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Fifty years after the elucidation of lipopolysaccharides (LPS, endotoxin) as the principal
structure of Gram-negative bacteria activating the human immune system, its Gram-
positive counterpart is still under debate. Pyrogen tests based on the human monocyte
activation have been validated for LPS detection as an alternative to the rabbit test and,
increasingly, the limulus amebocyte lysate test. For full replacement, international valida-
tions with non-endotoxin pyrogens are in preparation. Following evidence-based medicine
approaches, a systematic review of existing evidence as to the structural nature of the
Gram-positive pyrogen was undertaken. For the three major constituents suggested, i.e.,
peptidoglycan, lipoteichoic acids (LTA), and bacterial lipoproteins (LP), the questions to be
answered and a search strategy for relevant literature was developed, starting in Med-
Line. The evaluation was based on the Koch–Dale criteria for a mediator of an effect. A
total of 380 articles for peptidoglycan, 391 for LP, and 285 for LTA were retrieved of which
12, 8, and 24, respectively, fulﬁlled inclusion criteria. The compiled data suggest that for
peptidoglycan two Koch–Dale criteria are fulﬁlled, four for LTA, and two for bacterial LP. In
conclusion, based on the best currently available evidence, LTA is the only substance that
fulﬁlls all criteria. LTA has been isolated from a large number of bacteria, results in cytokine
release patterns inducible also with synthetic LTA. Reduction in bacterial cytokine induction
with an inhibitor for LTA was shown. However, this systematic review cannot exclude the
possibility that other stimulatory compounds complement or substitute for LTA in being
the counterpart to LPS in some Gram-positive bacteria.
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INTRODUCTION
Bacterial contaminations pose a risk for patients when injected
or present on medical implants. The traditional rabbit pyrogen
test introduced in the 1940s, in large part, has been replaced by
the limulus amebocyte lysate test (LAL, also known as bacterial
endotoxin test, BET). Shortcomings of both tests have been dis-
cussed elsewhere (Hartung et al., 2001; Schindler et al., 2009). A
number of tests based on the human fever reaction have been
assessed in two international validation studies (Hoffmann et al.,
2005; Schindler et al., 2006). Four tests have been considered vali-
dated for the detection of LPS in the respective peer-reviews by the
European, US, and Japanese validation bodies and have been for-
mally accepted by European Pharmacopeia and the US Food and
Drug Administration. The validated tests are the human whole
blood test measuring IL-1β, ist variant using cryopreserved whole
blood, the peripheral blood mononuclear cell (PBMC) test mea-
suring IL-6 and the MonoMac-6 cell line measuring IL-6. They are
commonly referred to now as monocyte activation tests (MAT).
The limited database from the validation studies as to non-LPS
pyrogens did not, however, allow considering them validated as
full replacement for the rabbit test, pointing to the need for novel
validation efforts. For these studies it is necessary to understand
the structural nature of Gram-positive pyrogens.
The scientiﬁc literature on Gram-negative lipopolysaccha-
rides (LPS) includes about 50,000 Medline-listed articles. Gram-
positive bacteria are by no mean less important, either clinically
or as pyrogens, but neither has a structural counterpart for the
induction of inﬂammatory reactions such as cytokine release
by macrophages been unambiguously identiﬁed nor made avail-
able to give rise to similar scientiﬁc literature. At the same time,
our understanding of recognition mechanisms is continuously
expanding (Triantaﬁlou et al., 2002; Draing et al., 2008b; Bauer
and Müller, 2009; Beutler, 2009; Kumar et al., 2009).
The extent of scientiﬁc publications in many areas has made it
very difﬁcult to follow a given topic. One possible method to man-
age this overwhelming literature is meta-analysis, which follows
well deﬁned rules and represents a possibility means of condens-
ing our current state of knowledge from the existing literature.
Systematic reviews with meta-analysis of compiled evidence are
the principal approach of evidence-based medicine (EBM). Sys-
tematic reviews have to be distinguished from the more common
narrative reviews in the life sciences: a systematic review answers
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a very narrow set of precisely deﬁned questions. The strategies for
identifying relevant evidence (typically by a decision tree) and how
to qualify, include, exclude, compile, and interpret this evidence are
predeﬁned and reviewed. The result is expressed, if possible, with
a measure of uncertainty. Neugebauer and Holaday (1993) ﬁrst
showed that such EBM approaches can be translated from clinical
studies to animal and in vitro ﬁndings.
The advantages and shortcomings of systematic reviews have
been widely discussed (Carr, 1989; Chalmers, 1989; Green, 1989;
Neugebauer and Lorenz, 1989; Oettinger, 1989). It is probable
that the application of a tree of yes/no decisions raises new faults,
and the preference to use methodological criteria for the selec-
tion of publications will lead to the simple result that the most
actual methods deliver the most accurate data. Construction of
a decision tree starts from a subjective point of view and may
not necessarily be correct. In spite of such limitations, systematic
reviews and meta-analysis appear to represent the most appropri-
ate methods to date for extracting the current state of art from the
literature.
Here, the approach of a systematic review was taken to
compile current best evidence for a causal role of peptidogly-
can, lipoteichoic acids (LTA), and LP as inducers of human
monocyte/macrophage inﬂammatory cytokine release, i.e., also as
human pyrogens.
AIM
Different structures of the Gram-positive cell wall have been
proposed as inducers of cytokine release (pyrogens) in human
monocyte/macrophages. In a systematic review adopting princi-
ples of EBM, the fulﬁllment of Koch–Dale (K/D) postulates was
evaluated for the three most prominent candidate inducers of
cytokine release LTA, lipoproteins (LP), and peptidoglycan (PGN).
To exclude a species discrepancy between the recognition of bac-
terial cell wall components in human or animals, only articles on
primary human monocytes/macrophages and derived cell lines
were used.
Dale adapted the Koch criteria of one cause-one disease to
chemical factors as early as 1929 (Dale, 1929). Koch–Dale criteria
adapted to the relevant question are:
1. Evidence for presence of LTA, PGN, or LP in cytokine-inducing
bacteria
2. Synthesis inhibition of LTA, PGN, or LP impairs cytokine
induction
3. Exposure to isolated LTA, PGN, or LP induces cytokine
induction
4. Blocking of LTA, PGN, or LP by antibodies or antagonists
prevents or reduces cytokine induction
K/D CRITERION 1
DATABASE FOR K/D CRITERION 1
First, it was important to verify whether the three analyzed surface
molecules were found in or even puriﬁed from cytokine-inducing
Gram-positive bacteria. PGN is well known to be ubiquitous
in Gram-positive bacteria (Vollmer and Holtje, 2004), whereas
some Gram-positive bacteria lack LTA, i.e., several Micrococci
(M. luteus, M. ﬂavus, M. sodonensis), Biﬁdobacterium biﬁdum and
Mycobacteria (Owen and Salton, 1975; Sutcliffe and Shaw, 1991).
Bacterial LP are also essential for Gram-positive bacteria (Bev-
eridge, 1999; Navarre and Schneewind, 1999), but we searched
systematically information about isolation of these structures
(Table 3). For K/D criterion 1 we therefore focused on identifying
publications that isolated LTA from Gram-positive bacteria. Using
the keywords “isolation lipoteichoic acid Gram-positive bacteria,”
we identiﬁed 179 publications from the library of theU.S.National
Library of Medicine and the National Institutes of Health (NCBI).
All publications were collected in full length; their abstracts, key
words, headlines, and authors were stored as a data ﬁle. These
reports were screened also for information on bacteria lacking
LTA; a secondary search was undertaken to identify for these spe-
ciﬁc bacteria reports on cytokine induction (or the lack thereof),
as well as other speciﬁc cytokine-inducing cell wall components
reported for these bacteria.
SELECTION OF THE LITERATURE FOR K/D CRITERION 1
To identify the publications that isolated LTA, the pool of publica-
tions was preselected according to decision tree 1 (Figure 1) and
was constructed with the following demands:
1. Original article on isolation of LTA
Only original articles that were able to isolate LTA conﬁrmed
by structural analysis were included; articles reporting only the
use of commercial LTA preparations were excluded and reviews
were not taken into account, nor were publications that did
not reveal detailed information about the isolation procedure
of LTA.
2. Methods appropriate
Appropriate methods were hot or cold phenol extraction with
subsequent gel chromatography, chloroform–methanol, or
butanol extraction, hydrophobic interaction chromatography
(HIC) and ion-exchange chromatography for puriﬁcation.
The two criteria led to 58 articles out of 179 publications and
are listed in Table 1.
K/D CRITERION 2
DATABASE FOR K/D CRITERION 2
The identiﬁcation of literature on inhibition or even deletion of
the synthesis of one of the surface molecules and the respective
effect on cytokine induction by the bacteria was the scope for
K/D criterion 2. Thus, deletion mutants of Gram-positive bacteria
for LTA or LP were searched for; PGN was excluded in this case
being the main component of the Gram-positive cell wall and a
FIGURE 1 | Decision tree 1 (Koch–Dale criterion 1).
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Table 1 | List of publications for isolation of LTA after application of decision tree 1.
Name Bacteria Reference Isolation method
Serological studies on the teichoic acids of Lactobacillus
plantarum
Lactobacillus plantarum Knox andWicken
(1972)
Phenol, gel chromatography,
gel chromatography, gel chro-
matography
Comparative studies on the isolation of membrane
lipoteichoic acid from Lactobacillus fermenti
Lactobacillus fermenti Wicken et al.
(1973)
Chloroform–methanol
Pneumococcal Forssman antigen. A choline-containing
lipoteichoic acid
Pneumococci Briles and
Tomasz (1973)
Chloroform–octanol
Lipoteichoic acid localization in mesosomal vesicles of
Staphylococcus aureus
Staphylococcus aureus (ATCC 6538P) Huff et al. (1974) Chloroform–methanol
Characterization of group N streptococcus lipoteichoic
acid
Streptococcus lactis (ATCC 9936) Wicken and Knox
(1975)
Phenol, gel chromatography
Lipoteichoic acid and lipoteichoic acid carrier in
Staphylococcus aureus H
Staphylococcus aureus H Duckworth et al.
(1975)
Phenol, gel chromatography
Extraction and puriﬁcation of lipoteichoic acids from
gram-positive bacteria
Staphylococcus aureus H,
Micrococcus 2102, Bacillus subtilis
168, Bacillus subtilis W-23
Coley et al.
(1975)
Phenol, gel chromatography
Cellular localization of lipoteichoic acid in Streptococcus
faecalis
Bacillus licheniformis 6346 MH-1 Joseph and
Shockman (1975)
Phenol, gel chromatography
Trihexosyldiacylglycerol and acyltrihexosyldiacylglycerol
as lipid anchors of the lipoteichoic acid of Lactobacillus
casei DSM 20021
Lactobacillus casei DSM 20021 Nakano and
Fischer (1978)
Phenol, gel chromatography
Puriﬁcation of lipoteichoic acids by using phosphatidyl
choline vesicles
Streptococcus mutans BHT, AHT Silvestri et al.
(1978)
Gel ﬁltration, HIC
Alanine ester-containing native lipoteichoic acids do not
act as lipoteichoic acid carrier. Isolation, structural and
functional characterization
Staphylococcus aureus (DSM 20233),
Lactobacillus helveticus (DSM 20075),
Streptococcus lactis (NCDO 712)
Fischer et al.
(1980)
HIC
Isolation of a Bacillus globigii cell wall component
involved in binding to human lymphocytes
Bacillus globigii Shockley and
Kleinman (1982)
Phenol, gel chromatography
Immunization of rhesus monkeys with Streptococcus
mutans, Lactobacillus acidophilus and lipoteichoic acid
for protection against dental caries
Streptococcus mutans Caldwell and
Lehner (1982)
Phenol, gel chromatography
Association of elevated levels of cellular lipoteichoic acids
of group B streptococci with human neonatal disease
Group B streptococci (GBS), different
strains
Nealon and
Mattingly (1983)
Phenol, gel chromatography
Improved preparation of Lipoteichoic acids Bacillus licheniformis DSM 13,
Lactobacillus casei DSM 20021,
Staphylococcus aureus DSM 20233,
Streptococcus faecalis ATCC 9790,
Streptococcus faecalis subsp.
zymogenes Kiel27138, Streptococcus
luctis Kiel42172, Streptococcus lactis
NCDO 712, Streptococcus pyogenes
I1 D698, Micrococcus varians ATCC
29750
Fischer et al.
(1983)
Phenol, gel chromatography,
HIC
Lipoteichoic acid from Listeria monocytogenes Listeria monocytogenes Hether and
Jackson (1983)
Phenol, gel chromatography
Structure of the lipoteichoic acids from Biﬁdobacterium
biﬁdum spp. pennsylvanicum
Biﬁdobacterium biﬁdum spp.
pennsylvanicum
Op den Camp
et al. (1984)
Phenol, gel chromatography
Activation of the alternative complement pathway by
pneumococcal lipoteichoic acid
Streptococcus pneumoniae R36A Hummell et al.
(1985)
Chloroform–methanol
Chemical properties and immunobiological activities of
streptococcal lipoteichoic acids
Streptococcus pyogenes Sv,
Streptococcus mutans 6715, and
Streptococcus sanguis ATCC 10556
Hamada et al.
(1985)
Phenol, gel chromatography
(Continued)
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Table 1 | Continued
Name Bacteria Reference Isolation method
Comparative studies of lipoteichoic acids from several
Bacillus strains
Bacillus subtilis, Bacillus licheniformis,
Bacillus pumilus, Bacillus coagulans,
Bacillus megaterium
Iwasaki et al.
(1986)
Phenol, gel chromatography
Lipoteichoic acids in Lactobacillus strains that colonize
the mouse gastric epithelium
Lactobacillus fermentum, Lactobacillus
leichmannii, Lactobacillus reuteri,
Lactobacillus acidophilus, Lactobacillus
murinus
Sherman and
Savage (1986)
Phenol, gel chromatography
Structural studies on lipoteichoic acids from four Listeria
strains
Listeria monocytogenes Uchikawa et al.
(1986)
Phenol, gel chromatography
Structural studies of a teichoic acid from Streptococcus
agalactiae type III
Streptococcus agalactiae type III Erbing et al.
(1986)
Phenol, gel chromatography
Lipoteichoic acid from Bacillus subtilis subsp. niger WM:
isolation and effects on cell wall autolysis and turnover
Bacillus subtilis subsp. niger WM Meyer and
Wouters (1987)
Phenol, gel chromatography
Mediation of Staphylococcus saprophyticus adherence to
uroepithelial cells by lipoteichoic acid
Staphylococcus saprophyticus Teti et al. (1987) Phenol, gel chromatography
“Lipoteichoic acid” of Biﬁdobacterium biﬁdum
subspecies pennsylvanicum DSM 20239. A lipoglycan
with monoglycerophosphate side chains
Biﬁdobacterium biﬁdum subsp.
pennsylvanicum DSM 20239
Fischer (1987) Phenol, gel chromatography
Stimulation of human monocyte chemiluminescence by
staphylococcal lipoteichoic acid
Staphylococcus saprophyticus strains
S1 and S35
Ohshima et al.
(1988)
Phenol, gel chromatography
Structure and glycosylation of lipoteichoic acids in
Bacillus strains
Bacillus cereus (4 strains), Bacillus
subtilis (5 strains), Bacillus
licheniformis (1 strain), Bacillus
polymyxa (2 strains), and Bacillus
circulans (3 strains)
Iwasaki et al.
(1989)
Phenol, gel chromatography
Distribution analyses of chain substituents of lipoteichoic
acids by chemical degradation
Lactococcus lactis Kiel 48337 Schurek and
Fischer (1989)
Phenol, gel chromatography
Occurrence and structure of lipoteichoic acids in the
genus Staphylococcus
Staphylococcus aureus, S. capitis DSM
20326, S. carnosus DSM 20501, S.
epidermidis DSM 20044, S.
hemolyticus DSM 20263, S.
saccharolyticus DSM 20359, S. sciuri
DSM 20352, S. warneri DSM 20316, S.
cohnii DSM 20260, S. hominis DSM
20328, S. saprophyticus DSM 20229,
S. simulans DSM 20322
Ruhland and
Fiedler (1990)
Phenol, gel chromatography
On the basic structure of poly(glycerophosphate)
lipoteichoic acids
24 Gram-positive bacteria of the
genera Bacillus, Enterococcus,
Lactobacillus, Lactococcus, Listeria,
Staphylococcus, and the streptococcal
pyogenic and oral group
Fischer et al.
(1990)
Phenol, HIC
Structure of macroamphiphiles from several
Biﬁdobacterium strains
Biﬁdobacterium biﬁdum YIT 4007 and
YIT 4013, Biﬁdobacterium breve YIT
4010 andYIT 4014, and Biﬁdobacterium
longum YIT 4021
Iwasaki et al.
(1990)
Phenol, gel chromatography
Isolation and characterization of lipoteichoic acid, a cell
envelope component involved in preventing phage
adsorption, from Lactococcus lactis subsp. cremoris
SK110
Lactococcus lactis subsp. cremoris
SK110
Sijtsma et al.
(1990)
Chloroform–methanol
Molecular analysis of lipoteichoic acid from
Streptococcus agalactiae
S. pyogenes 147, S. mutans GS-5,
Enterococcus hirae ATCC 9790, S.
agalactiae 110,
Maurer and
Mattingly (1991)
Phenol, gel chromatography
(Continued)
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Table 1 | Continued
Name Bacteria Reference Isolation method
Separation of the poly(glycerophosphate) lipoteichoic
acids of Enterococcus faecalis Kiel 27738, Enterococcus
hirae ATCC 9790, and Leuconostoc mesenteroides DSM
20343 into molecular species by afﬁnity chromatography
on concanavalin A
Enterococcus faecalis Kiel27738,
Enterococcus hirae ATCC 9790, and
Leuconostoc mesenteroides DSM
20343
Leopold and
Fischer (1991)
Phenol, gel chromatography,
HIC
Small and medium-angle X-ray analysis of bacterial
lipoteichoic acid phase structure
Biﬁdobacterium biﬁdum DSM 20239,
Enterococcus hirae (Streptococcus
faecium) ATCC 9790, Lactococcus
garvieae NCDO 2155, Listeria
welshimeri SLCC 5354, and S. aureus
DSM 20233
Labischinski
et al. (1991)
Phenol, gel chromatography,
HIC
Hydrophobic interaction chromatography fractionates
lipoteichoic acid according to the size of the hydrophilic
chain: a comparative study with anion-exchange and
afﬁnity chromatography for suitability in species analysis
Enterococcus faecalis Kiel 27738
(DSM 20371)
Leopold and
Fischer (1992)
Phenol, gel chromatography,
HIC
d-Alanyl-lipoteichoic acid in Lactobacillus casei : secretion
of vesicles in response to benzylpenicillin
Lactobacillus casei ATCC 7469 Pollack et al.
(1992)
Phenol, gel chromatography
Molecular analysis of lipid macroamphiphiles by
hydrophobic interaction chromatography, exempliﬁed with
lipoteichoic acids
Enterococcus hirae NICB 8191,
Lactococcus garvieae NCFB 2730,
Staphylococcus aureus
Fischer (1993) Phenol, gel chromatography,
HIC
The structure of pneumococcal lipoteichoic acid. Improved
preparation, chemical, and mass spectrometric studies
Streptococcus pneumoniae R6 Behr et al.
(1992)
Chloroform–methanol
Isomalto-oligosaccharide-containing lipoteichoic acid of
Streptococcus sanguis. Basic structure
Streptococcus sanguis DSM 20567
and of DSM 20068
Kochanowski
et al. (1993)
Phenol, gel chromatography,
HIC
Chemiluminescence of human polymorphonuclear
leukocytes after stimulation with whole cells and cell wall
components of Staphylococcus epidermidis
Staphylococcus epidermidis Martinez-
Martinez et al.
(1993)
Phenol, gel chromatography
Competitive binding of calcium and magnesium to
streptococcal lipoteichoic acid
Streptococcus sanguis Rose and
Hogg (1995)
Phenol, gel chromatography,
HIC
Lipoteichoic acid inhibits remineralization of artiﬁcial
subsurface lesions and surface-softened enamel
Lactobacillus casei Damen et al.
(1995)
Phenol, gel chromatography
Cytokine-inducing glycolipids in the lipoteichoic acid
fraction from Enterococcus hirae ATCC 9790
Enterococcus hirae ATCC 9790 Suda et al.
(1995)
Chloroform–methanol
A lipoteichoic acid fraction of Enterococcus hirae activates
cultured human monocytic cells via a CD14-independent
pathway to promote cytokine production, and the activity
is inhibited by serum components
Enterococcus hirae (ATCC 9790) Arakaki et al.
(1998)
Phenol, HIC
Structure-function relationship of cytokine induction by
lipoteichoic acid from Staphylococcus aureus
S. aureus DSM 20233 Morath et al.
(2001)
Butanol-HIC
Production of IL-12 and IL-18 in human dendritic cells upon
infection by Listeria monocytogenes
L. monocytogenes EGD Kolb-Maurer
et al. (2003)
Phenol, gel chromatography
Characterization of lipoteichoic acids as Lactobacillus
delbrueckii phage receptor components
Lactobacillus delbrueckii Raisanen et al.
(2004)
Phenol, gel chromatography
Monoacyl lipoteichoic acid from pneumococci stimulates
human cells but not mouse cell
Streptococcus pneumoniae (strain
R36A)
Kim et al.
(2005)
Phenol, gel chromatography,
ion-exchange chromatography
Highly puriﬁed lipoteichoic acid from gram-positive
bacteria induces in vitro blood-brain barrier disruption
through glia activation: role of pro-inﬂammatory cytokines
and nitric oxide
S. aureus DSM 20233 Boveri et al.
(2006)
Butanol-HIC
Comparison of lipoteichoic acid from different serotypes
of Streptococcus pneumoniae
S. pneumoniae strain R6, S.
pneumoniae strain Fp23 (serotype 4)
Draing et al.
(2006)
Butanol-HIC
(Continued)
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Table 1 | Continued
Name Bacteria Reference Isolation method
Opsonic antibodies to Enterococcus faecalis strain 12030
are directed against lipoteichoic acid
Enterococcus faecalis strain 12030 Theilacker et al.
(2006)
Butanol-HIC
Butanol-extracted lipoteichoic acid induces in vivo
leukocyte adhesion
S. aureus DSM 20233 Finney et al.
(2007)
Butanol-HIC
Lipoteichoic acid isolated from Lactobacillus plantarum
inhibits lipopolysaccharide-inducedTNF-alpha production
in THP-1 cells and endotoxin shock in mice
L. plantarum K8 (KCTC10887BP) Kim et al. (2008) Butanol-HIC
Macroamphiphilic components of thermophilic
actinomycetes: identiﬁcation of lipoteichoic acid in
Thermobiﬁda fusca
Thermobiﬁda fusca and Rubrobacter
xylanophilus
Rahman et al.
(2009b)
Butanol-HIC
Differential immunostimulatory effects of Gram-positive
bacteria due to their lipoteichoic acids
Staphylococcus aureus, Lactobacillus
plantarum, Bacillus subtilis
Ryu et al. (2009) Butanol-HIC
Phenotypic variation in Streptomyces sp. DSM 40537, a
lipoteichoic acid producing actinomycete
Streptomyces sp. DSM 40537 Rahman et al.
(2009a)
Butanol-HIC
FIGURE 2 | Decision tree 2 (Koch–Dale criterion 2).
mutation in complete biosynthesis of PGN would lead to a failure
in growth and in surviving of theGram-positive bacterium.Hence,
we used the keywords “(mutation OR deﬁciency OR deﬁcient)
AND bacterial lipoproteins AND cytokines” or “(mutation OR
deﬁciency OR deﬁcient) AND lipoteichoic acid AND cytokines,”
revealing 62 publications for bacterial lipoproteins and 58 for LTA
from NCBI.
VERIFICATION OF K/D CRITERION 2
To identify publications that give information about a deletion
mutant of either LTA or bacterial LP, the pool of publications
was selected according to decision tree 2 (Figure 2) and was
constructed with the following requirements:
1. Original article on a deletion mutant of LTA or bacterial
lipoproteins, respectively
Only original articles were included; abstracts and reviews were
excluded.
2. Gram-positive bacteria used?
Publication on Gram-negative bacteria were excluded.
3. Experiments done with human primary cells or cell lines?
Only studies with primary human monocytes/macrophages
and/or cell lines derived from them were included. Publications
reporting only animal experiments and/or animal cells were
excluded, and in articles with both human and animal models
only the human cell experiments were taken into account for
our analysis.
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4. Controls appropriate?
The corresponding wildtype should lead to a normal cytokine
induction.
5. Signiﬁcant inﬂuence by deletion of LTA or bacterial lipopro-
teins
Does the mutant lead to an inhibition of cytokine induction?
The demands led to three publications out of 87 (Table 2) for
bacterial LP and two for LTA (Table 2).
K/D CRITERIA 3 AND 4
DATABASE FOR K/D CRITERIA 3 AND 4
Using the keywords “(bacteria AND lipoteichoic acid) AND
cytokines” or “(bacteria AND peptidoglycan) AND cytokines” or
“(bacteria AND lipoproteins) AND cytokines” we obtained 285
publications for lipoteichoic acid, 380 publications for peptido-
glycan, and 391 publications for lipoproteins from NCBI. All
publications were again collected in full length, and pre-selection
was done using the following parameters: The pre-selection and
databasewereused forK/Dcriteria 3 and4. Literature cited in these
articles constituted a secondary pool of references to complement
the systematic analysis.
PRE-SELECTION OF THE LITERATURE FOR K/D CRITERIA 3 AND 4
In a ﬁrst step, the pool of publications was preselected according
to decision tree 3, as shown in Figure 3. This ﬁlter was set to con-
centrate the data on basic quality standards and was constructed
with following demands:
1. Original article on LTA or PGN or bacterial lipoproteins and
cytokines
Only original articles were included: abstracts and reviews
were transferred to pool 2 for background information, as
mentioned before.
2. Maximum age of the article must be 10 years
The scientiﬁc understanding about pattern recognition mole-
cules (pathogen-associated molecular pattern, PAMP) of bac-
teria and the respective receptors activating the innate immune
system has advanced enormously over the last decade, as have
technologies for structural analysis and preparation. Namely
the identiﬁcation of Toll-like receptors and the introduction of
NMR and mass-spectroscopy for purity as well as exclusion of
Gram-negative endotoxin have advanced strongly.We therefore
limited the age of the publications to 10 years. The secondary
pool of literature formed by the citations in these articles was
not restricted by this criterion in order not to lose valuable
supporting information still relevant for today’s discussion.
3. Experiments done with human primary cells or cell lines?
To exclude a species discrepancy between the recognition of
bacterial cell wall components in human or animals, only
human studies with primary cells and/or cell lines derived
from them were considered. Publications reporting only ani-
mal experiments and/or animal cells were not included, and in
articles with both human and animal models only the human
experiments were taken into account for analysis.
4. Number of replicates appropriate?
To ensure that the results of the experiments reported were
accurate enough, only studies performed at least in triplicates
and in at least three independent experiments were included.
For primary cell experiments it was necessary to use at least
three different donors.
5. End points appropriate?
The following parameters were accepted: Cytokine releasemea-
sured by ELISA or FACS, luciferase assay to determine NFκB
activation, PCR, and microarray analysis to determine gene
activation.
6. Endotoxin exclusion (for sub analysis)
To ensure that theGram-positive cell wall componentswere not
contaminated by endotoxin we ﬂagged studies that reported a
method for endotoxin exclusion, such as limulus amebocyte
lysate assay, limulus anti-LPS factor (LALF), polymyxin B or
other indications for substances without endotoxin content.
This criterion did not lead to an exclusion of the publica-
tion but was used to analyze whether a possible endotoxin
contamination impacts on the results.
Table 2 | Results for Koch–Dale criterion 2 for bacterial lipoproteins and LTA.
Reference Bacteria Mutation Cytokines Outcome
BACTERIAL LIPOPROTEINS
Stoll et al. (2005) Staphylococcus aureus Diacylglycerol transferase (lgt)
deletion
IL-6, IL-8, MCP-1,
TNF, IL-10
S.a.Δlgt attenuated in growth in nutrient
limited medium, induction of cytokines is
reduced
Wilkinson et al. (2009) Mycobacterium
tuberculosis
Mutation in Delta 19 gene
responsible for the production
of the 19-kDa lipoprotein
IL-1β, TNF, IL-12 M.t. Δ19 leads to reduced IL-1β induction,
but TNF and IL-12 release is unaffected
Rusch et al. (2007) Mycobacterium
tuberculosis
Mutation in Delta 19 gene
responsible for the production
of the 19-kDa lipoprotein
IL-1β, TNF M.t. Δ19 leads to reduced IL-1β induction,
but TNF release is unaffected
LTA
Perea Velez et al. (2007) Lactobacillus rhamnosus Deletion of dlt operon
responsible for LTA alanylation
IL-10, TNF IL-10 release signiﬁcantly reduced for dlt
mutant, TNF unaffected compared to wt
Grangette et al. (2005) Lactobacillus plantarum
NCIMB8826
Deletion of dlt operon
responsible for LTA alanylation
TNF, IL-12, IFNγ,
IL-10
TNF, IL-12, and INFγ signiﬁcantly reduced
for dlt mutant, IL-10 increased
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FIGURE 3 | Decision tree 3 (pre-selection of the literature for Koch–Dale criteria 3 and 4).
VERIFICATION OF K/D CRITERION 3 (FIGURE 4)
1. Determination of cytokine induction after admission of one
of the three bacterial surface molecules
Did the applied substance induce cytokine release?
2. Applied substance deﬁned?
The employed PGN, LTA, or lipoprotein had to be speciﬁed
with respect to puriﬁcation grade and source.
3. Controls appropriate?
In this case,controls in the absenceof the investigatedmolecules
should not result in signiﬁcant cytokine induction.
4. Dose- or concentration-dependent response?
Does the puriﬁedmaterial respond in a dose- or concentration-
dependent manner, e.g., higher cytokine levels at higher
concentrations of the stimulus?
VERIFICATION OF K/D CRITERION 4 (FIGURE 5)
1. Determination of cytokine induction in the presence of one
of the three bacterial surface molecules
Did the applied substance induce signiﬁcant cytokine release?
2. Exclusion of toxic effects by the antibody or antagonist
In this case, the antibody against or antagonist of the three bac-
terial surface molecules should not have a toxic effect on the
cells used.
3. Applied antibody or antagonist deﬁned?
The employed antibody or antagonist had to be speciﬁed with
respect to puriﬁcation grade and source.
4. Controls appropriate?
In this case, controls with admission of the antibody or
antagonist should not result in signiﬁcant cytokine induction.
5. Signiﬁcant change in cytokine release after admission of the
antibody or antagonist?
The presence of an antibody or antagonist should lead to a
signiﬁcantly reduced cytokine induction.
If all requirements of the decision trees were fulﬁlled, then the
probability of correct results is high (best evidence). The possible
answers were:
Yes –The study demonstrated that the puriﬁed and applied sub-
stance leads to a signiﬁcant cytokine-inducing activity in human
monocytes/macrophages and can therefore be considered as an
immunostimulatory molecule.
No – The substance does not display a sufﬁcient
immunostimulatory activity of cytokine induction in human
monocytes/macrophages under controlled conditions in the given
study.
RESULTS
PRESENCE OF LTA, BACTERIAL LIPOPROTEINS OR PGN IN
GRAM-POSITIVE BACTERIA (K/D CRITERION 1)
Peptidoglycan and bacterial lipoproteins are essential in Gram-
positive bacteria. PGNhas been positively identiﬁed and structural
variants for many species are known, thereby the criterion is con-
sidered fulﬁlled; in the absence of a structural identiﬁcation of a
general immunostimulatoryLP,which is responsible across awider
variety of bacterial species for cytokine induction, only the general
presence of LP can be assumed, but the criterion cannot be con-
sidered veriﬁed. We identiﬁed six reports on LP isolation from ﬁve
bacterial species, largely different in suggested structure, however,
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FIGURE 4 | Decision tree 4 (Koch–Dale criterion 3).
FIGURE 5 | Decision tree 5 (Koch–Dale criterion 4).
as presented in Table 3. The focus was to ﬁnd publications in
which an isolation of LTA was described. Fifty-eight publications
showed an isolation of LTAusing different puriﬁcation variants for
81 different bacterial strains, as shown in Table 1. It is therefore
concluded that Koch–Dale criterion 1 is fulﬁlled for PGN and LTA
as ubiquitous surface molecules. Given the limitation that it is not
known, which LP is responsible for cytokine induction, however,
makes it impossible to verify whether the respective speciﬁc LP
structures are ubiquitous.
DELETION OF GENES INVOLVED IN BIOSYNTHESIS OF LTA, BACTERIAL
LIPOPROTEINS, AND PGN IN GRAM-POSITIVE BACTERIA
(K/D CRITERION 2)
The structure of Gram-positive bacterial cell walls consists of a
large PGN layer. This layer is mainly responsible for the intact
composition of the cell wall that a Gram-positive mutant lacking
PGN would be unable to grow and survive. In line with this, there
is currently no publication available reporting a mutant free of
PGN and its effect on cytokine release; thus the criterion could
not be satisﬁed for PGN.
The references for the deletion of genes involved in biosyn-
thesis of lipoproteins show a decrease in cytokine induction,
using a S. aureus mutant (Stoll et al., 2005) and a M. tubercu-
losis one (Stewart et al., 2005; Wilkinson et al., 2009), as shown
in Table 2. For alteration of LTA, we found two publications
showing decrease in IL-10 (Perea Velez et al., 2007) and TNF,
IL-12, and IFNγ (Grangette et al., 2005) release, as shown in
Table 2.
These ﬁndings show the importance of the two surface mol-
ecules, and the K/D criterion 2 can be considered as fulﬁlled for
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Table 3 | Isolation of different Gram-positive lipoproteins.
Name Bacteria Reference Isolation method
Isolation and characterization of a C12-lipopeptide produced by
Bacillus subtilis HSO 121
Bacillus subtilis
HSO 121
Liu et al. (2008) Chromatographic
Isolation and structural analysis of bamylocin A, novel lipopeptide
from Bacillus amyloliquefaciens LP03 having antagonistic and
crude oil-emulsifying activity
Bacillus
amyloliquefaciens
LP03
Lee et al. (2007) Methanol, silica gel column
chromatography, HPLC
Isolation, characterization, and investigation of surface and
hemolytic activities of a lipopeptide biosurfactant produced by
Bacillus subtilis ATCC 6633
Bacillus subtilis
ATCC 6633
Dehghan-Noude et al. (2005) HCl extraction
Lichenysins G, a novel family of lipopeptide biosurfactants from
Bacillus licheniformis IM 1307: production, isolation, and structural
evaluation by NMR and mass spectrometry
Bacillus
licheniformis IM
1307
Grangemard et al. (1999) HPLC
Isolation and partial characterization of theTriton X-100 solubilized
protein antigen from Mycobacterium tuberculosis
Mycobacterium
tuberculosis
Kim et al. (1999) Triton X-100
WS1279, a novel lipopeptide isolated from Streptomyces
willmorei. Fermentation, isolation, and physico-chemical properties
Streptomyces
willmorei
Tanaka et al. (1993) Ethyl Acetate
LTA and LP. The lack of evidence for PGN for criterion 2 does
not impair a conclusion as to its possible importance as immune
stimulus.
CYTOKINE INDUCTION OF LTA, BACTERIAL LIPOPROTEINS, AND PGN IN
GRAM-POSITIVE BACTERIA IN THE HUMAN SYSTEM (K/D CRITERION 3)
Isolation or favorably chemical synthesis of PGN, LTA, and bacte-
rial lipoproteins and their ability to induce cytokine induction in
human immune cells was investigated as K/D criterion 3. Pub-
lications for lipoproteins were divided in two parts, synthetic
lipoproteins such as Pam3CysK and isolation, and recombinant
lipoproteins.Asmentioned above,publicationswere distinguished
between those that provide information about exclusion of endo-
toxin contamination and that do not provide that information for
subanalysis.
Lipoteichoic acid
Sixteen publications with data for endotoxin exclusion revealed
a release of pro-inﬂammatory cytokines like IL-1β, IL-6, IL-
8, TNF, and G-CSF or the anti-inﬂammatory cytokine IL-10
in human whole blood, PBMCs, THP-1 cells, human primary
monocytes, or neutrophils (Table 4). Additionally, 10 publica-
tions without data for exclusion of endotoxin contaminations
found, in addition, a release of IL-2 in PBMCs, whereas TNF, IL-
1β, IL-6, IL-8, and IL-10 release was also found in the papers of
this non-endotoxin-exclusion group. Since IL-2 is not a mono-
cyte/macrophage product, this result does not add to the conclu-
sions drawn from the higher quality evidence from studies exclud-
ing endotoxin contaminations. It is noteworthy, however, that ﬁve
publications are available describing LTA structures derived by
chemical synthesis, excluding endotoxin contamination, show-
ing cytokine induction in human monocytes/macrophages. No
publications were retrieved in which isolated or synthesized LTA
were not capable of inducing cytokine release in human mono-
cytes/macrophages. It is concluded that there is unambiguous
evidence that LTA is capable of activating cytokine release by
human monocytes/macrophages.
Peptidoglycan
If endotoxin-free PGN is used as a stimulus for inducing cytokine
release in human immune cells, TNF, IL-1β, IL-6, IL-8, IL-10,GM–
CSF, and RANTES were detected (Table 5). Publications with-
out information about a use of a sufﬁcient endotoxin exclusion
revealed similar results, although they mainly used commercially
available PGN. However, no synthetic PGN has been reported to
induce cytokine release. Furthermore, publications were found in
the secondary literature pool showing that further puriﬁcation of
PGN abrogated cytokine induction (Travassos et al., 2004), chal-
lenging the capability of PGN to activatemonocytes/macrophages.
They were excluded here, however, since animal cells were used.
Note that several reports showed that the supposed active pattern
of PGN, i.e., muropeptides, if free of endotoxin, does not activate
cytokine release (for review see Traub et al., 2006). In conclusion,
the evidence of PGN inducing cytokine release is limited.
Bacterial lipoproteins
Isolation and structural analysis of lipoproteins from Gram-
positive bacteria was done only in a few cases, so we divided
retrieved literature into two subgroups, i.e., ﬁve reports on syn-
thetic lipoproteins (Table 6) and three reports on recombinant
and isolated ones (Table 6). L-OspA from Borrelia burgdorferi is
a commercially available recombinant lipoprotein and leads to a
release of IL-1β, IL-6, IL-10, TNF, and IL-12 in THP-1 cells (DiRita
et al., 2000;Giambartolomei et al., 2002). Triton extracted lipopro-
teins were obtained fromMycoplasma genitalium (Wu et al., 2008).
The lipoprotein extracted from M. genitalium was used as a stim-
ulus for THP-1 cells and tested for an endotoxin contamination
with polymyxin B led to a release of TNF, IL-1β, and IL-6.
Synthetic lipoproteins such as PAM3CysK and PAM2CysK have
biological activity, which is shown as induced release of TNF
and IL-6 in publications with data reporting endotoxin exclusion
and INF-γ, IL-12, TNF, IL-8, and IL-6 in non-endotoxin tested
PAM2CysK and PAM3CysK. In one publication (Greene et al.,
2005), MALP-2 leads to a release of IL-6 and IL-8 but it was not
tested for endotoxin contamination.
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Table 4 | Publications after fulfillment of decision tree for K/D criterion 3 for LTA.
Reference Substance Source of substance Cytokines Cells Endotoxin exclusion
Deininger et al. (2007) LTA Synthetic TNF, IL-8 Whole blood LAL
Hasiwa et al. (2007) PGN, LTA Commercial, isolated IL-1β Whole blood LAL
Deininger et al. (2008) LTA Isolated IL-8, IL-1β, IL-6, TNF, G-CSF, IL-10 Whole blood LAL
Kim et al. (2007b) LTA Isolated, commercial IL-10, IL-23 THP-1 Poly B
Uehara et al. (2002) LTA, PGN Commercial IL-8 IFN primed HSC2 Poly B
Wang et al. (2000) LTA, PGN Isolated TNF, IL-1β, IL-6 Whole blood Poly B
Bucki et al. (2008) LTA Commercial IL-8 Neutrophils LAL
Meron-Sudai et al. (2008) LTA, PAM3 Isolated IL-1β Whole blood, monocytes LAL
Kim et al. (2008) LTA Isolated TNF THP-1 LAL
Draing et al. (2008a) LTA Isolated TNF Whole blood, PBMC LAL
Draing et al. (2006) LTA Isolated TNF-, IL-8, IL-10, G-CSF, IL-1β PBMC, whole blood LAL
Mueller et al. (2006) LTA Isolated TNF, IL-6 PBMC, Monocytes Not TLR4 dependent
Levels et al. (2003) LTA Commercial TNF Whole blood LAL (<19ng/mg LTA
Deininger et al. (2003) LTA Synthetic IL-1β, TNF, IL-6, IL-8, IL-10 Whole blood LAL
Morath et al. (2002a) LTA Isolated, synthetic TNF, IL-1β, IL-6, IL-10 Whole blood, PBMC LAL
Morath et al. (2001) LTA Isolated TNF Whole blood LAL
Kim et al. (2007a) MDP, LTA Commercial, isolated TNF-, IL-12 p40, and IL-10 DC –
Henneke et al. (2005) LTA Isolated, commercial IL-8 PBMC, HEK293 –
Grangette et al. (2005) LTA Isolated IL-1β, TNF, IL-8, IL-6 PBMC –
Schroder et al. (2003) LTA Isolated TNF PBMC –
Jacinto et al. (2002) LTA Isolated TNF, IL-1β THP-1 Not TLR4 dependent
Plitnick et al. (2001) LTA Isolated IL-2 PBMC –
Talreja et al. (2004) PGN, LTA Commercial IL-6 HUVEC Poly B
Morath et al. (2002b) LTA Synthetic TNF Whole blood –
Stadelmaier et al. (2006) LTA Synthetic TNF, IL-8 Whole blood –
Into et al. (2007) PGN, LTA Commercial IL-10 THP-1 –
Table 5 | Publications after fulfillment of decision tree for K/D criterion 3 for PGN.
Reference Substance Source of substance Cytokines Cells Endotoxin
Wolfert et al. (2002) PGN, muramyl dipeptide (MDP) Isolated, commercial TNF MonoMac-6 Poly B
McCurdy et al. (2003) LP, PGN Isolated, commercial IL-1β, IL-6, RANTES, GM–CSF Cord blood-derived
mast cells (CBMC)
LAL
Wang et al. (2000) LTA, PGN Isolated TNF, IL-1β, IL-6 Whole blood Poly B
Langer et al. (2008) PGN Isolated TNF Whole blood Poly B
Natsuka et al. (2008) PGN Isolated IL-8 THP-1 LAL
Uehara et al. (2005) MDP, PGN Commercial IL-8 THP-1 –
Into et al. (2007) PGN, LTA Commercial IL-10 THP-1 –
Eriksson et al. (2006) PGN Commercial IL-12, IL-15 THP-1 –
Uehara et al. (2006) PGN Commercial, isolated IL-8, MCP-1, IL-6, andTNF THP-1 –
In conclusion, cytokine induction has been reported for all
three substance classes, with only LTA having more than 10
qualifying papers.
BLOCKING OF LTA, BACTERIAL LIPOPROTEINS OR PGN BY ANTIBODIES,
ANTAGONISTS, OR INHIBITORS PREVENTS OR REDUCES CYTOKINE
RELEASE (K/D CRITERION 4)
Only one study was found for LTA (Draing et al., 2008a) where
TNF induction was signiﬁcantly reduced using polypropylene
glycol as an inhibitor for LTA. For PGN, no paper passed the
inclusion criteria. A paper from the secondary literature pool
was identiﬁed describing speciﬁc anti-LTA antibodies that aug-
mented recognition of LTA and cytokine response, hinting also at a
structure-speciﬁc intervention (Mancuso et al., 1994). Thus, there
is an evident lack of speciﬁc inhibitors and/or studies reporting
their effect being applied to block cytokine stimulation, especially
for LP and PGN.
DISCUSSION
This study compiled in a systematic manner the available evi-
dence for the major candidate molecules currently suggested as
representing in Gram-positive bacteria the functional counterpart
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Table 6 | Publications after fulfillment of decision tree for K/D criterion 3 for synthetic LP and recombinant or isolated LP.
Reference Substance Source of substance Cytokines Cells Endotoxin
SYNTHETIC LP
Wang et al. (2002) LP Commercial TNF, IL-6 THP-1 LAL
Schromm et al. (2007) LP Isolated TNF, IL-8 Monocytes, HEK293 Poly B
McCurdy et al. (2003) LP, PGN Isolated, commercial IL-1, IL-6, RANTES, GM–CSF Cord blood-derived
mast cells (CBMC)
LAL
Schroder et al. (2004) LP Commercial TNF PBMC –
Sieling et al. (2003) LP Commercial IL-12 p40, GM–CSF, IL-4 PBMC –
RECOMBINANT OR ISOLATED LP
Wu et al. (2008) Mycoplasma LP Commercial, isolated TNF, IL-1β, IL-6 THP-1 Poly B
DiRita et al. (2000) L-OSPA Commercial, isolated IL-6, IL-10, IL-12 (p40), TNF, IL-1β THP-1 LAL
Giambartolomei et al. (2002) L-OSPA Commercial, isolated IL-6, IL-10, and IL-12 THP-1 LAL
to Gram-negative lipopolysaccharides in innate immune activa-
tion such as the pyrogenic reaction. Cytokine induction in human
monocytes/macrophages and cell lines derived from these was
considered a sufﬁciently broad key event, for which data are avail-
able. The K/D criteria gave a generally accepted framework for the
analysis of causation of an effect by a given mediator.
Ameta-analysis of the threemost commonly consideredGram-
positive bacterial surface structures involved in immunostimu-
lation and cytokine release was more difﬁcult than anticipated.
The number of publications is huge, the information provided is
diverse, and the studies offer a variety of different settings, out-
comes, and results. Our restriction to human cell studies revealed,
on the one hand, more relevant information to the actual inter-
action between pathogens and the human immune system but,
on the other hand, led to a loss of interesting and important
pieces of evidence. Often the materials used either were not tested
for endotoxin (at least the information about a relevant test was
not provided) or commercial preparations were used without giv-
ing information about purity and contaminations. Commercial
preparations of LTA and PGN have a high risk of being impure
or contaminated (Gao et al., 2001; Morath et al., 2002a; Li et al.,
2008); there is no reason to assume that this is different for LP.
Furthermore, our own experience with PGN and LTA underscores
the importance of purity and exclusion of contaminants in the
isolated material. In the case of PGN, we could conﬁrm ﬁndings
of Travassos et al. (2004) that PGN is not able to induce cytokine
release in human monocytes when it is highly puriﬁed (Rockel
et al., 2011). Travassos and his co-workers used a mouse model
for investigation of cytokine induction, which led to an exclu-
sion of his studies in this meta-analysis based on the pre-selection
criteria.
In some studies, cytokine induction in human cell systems
was only a minor aspect of the paper, which led to difﬁculties
in drawing conclusions for our analysis. The main problem was
to ﬁnd studies using antagonists of or antibodies to LTA, PGN,
or bacterial lipoproteins, respectively, which leads to a lack of
conclusions for the K/D criterion 4 for all structures but LTA.
Such studies would help considerably our understanding of the
role of LP and PGN. As a possible substitute to provide evi-
dence for K/D criterion 4, reports could be used that show how
the blockade or abrogation of speciﬁc pattern recognition recep-
tors for the different PAMP impairs cell activation. However, this
requires knowledge of these receptors and their speciﬁcities as
well, as the central problem has been that the predominant tech-
niques used are knock-out-mice, thus restricting us to animal
models.
Taken together, our results indicate that among the pertinent
candidate molecules under discussion, i.e., LTA, PGN, and bac-
terial lipoproteins, only for LTA do the retrievable data support
all K/D criteria in a satisfactory manner (Table 7). It can there-
fore be considered as a PAMP, certainly not excluding others.
Furthermore, data available are not sufﬁcient to decide if the
Gram-positive PAMP can produce endotoxic shock-like reactions.
So far,only reports on liver injury in galactosamine-sensitizedmice
(Hermann et al., 2002) are available (Lehner et al., 2001). It still
remains to be elucidated, however, which receptors are involved
in this activation and whether and how other PAMP modulate
the process. Collecting more data, especially in human cell sys-
tems, will provide better information and more knowledge of the
interaction between LTA and the human innate immune system.
Furthermore, it will be important to ﬁnd out if LTA is a pre-
requisite for cytokine induction using bacteria that have atypical
LTAs or even have replaced LTA with other structures. Little is
known about these bacteria and their contribution to cytokine
release, with the exception of Mycobacteria like M. leprae and
M. tuberculosis, where it is suggested that the lipoarabinomannan
structures play an important role in cytokine induction (Barnes
et al., 1992; Dao et al., 2004). Propionibacteria, Biﬁdobacteria,
and Micrococci have no LTA (Sutcliffe and Shaw, 1991), but no
reports were retrieved regarding their cytokine-inducing capacity
in human monocytes/macrophages. Finally, strong evidence is
available from the fact that synthetic LTA shows a similar cytokine
proﬁle compared to the natural isolated substance,which supports
the importance of LTA in cytokine induction in humans (Morath
et al., 2002b; Deininger et al., 2003).
Bacterial lipoproteins also seem to play a role in cytokine
release, but it appears difﬁcult to isolate and purify them. The
majority of research is done with synthetic lipoproteins such as
PAM2Cys-K4 or PAM3Cys-K4, and it remains unclear whether
this reﬂects the stimulation by bacterial components. For the
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Table 7 | Fulfillment of the four K/D criteria for LTA, PGN, and LP
(criteria: 1–5 publications: +; 6–10 publications: ++; >10 publications:
+++).
LTA PGN LP
K/D 1 +++ Ubiquitous −
K/D 2 + Not possible +
K/D 3 +++ ++ ++
K/D 4 + − −
studies analyzed in this meta-analysis, the outcome is that bac-
terial lipoproteins only partially fulﬁll the ﬁrst three K/D criteria,
given that a ubiquitous general structure has not been identiﬁed
or made available by puriﬁcation or synthesis; the lack of studies
using antibodies or antagonists for these lipoproteins cause it to
fail criterion 4.
Peptidoglycan and its contribution as a PAMP, however, is a
subject of a long and ongoing discussion with regard to its con-
tribution to cytokine release and interaction with the human
immune system. Especially in Gram-positive bacteria, it appeared
to be important for detection by the immune system simply
because it is a major constituent of the total content of the Gram-
positive cell wall. PGN was ﬁrst considered to signal via TLR2
(Schwandner et al., 1999). Nucleotide oligomerization domain
(NOD)-like receptors, however (Girardin et al., 2003a,b), recog-
nizes PGN breakdown products. According to more recent studies,
PGN has to be internalized and digested for an immune reaction
(Wu et al., 2007), and highly puriﬁed PGN does not seem to be a
trigger for cytokine release (Travassos et al., 2004). However, these
reports were not included in our analysis due to the restriction
to the human system, and the studies noted were done in mice
or in murine cell systems. As mentioned before, our own stud-
ies support the ﬁndings of Travassos et al. (2004), using human
whole blood in this case (Rockel et al., 2011). These results are not
included in this analysis, either, as they were not published at the
time of literature search.
A key question not addressed in this systematic review, due to
the limited number of studies available, is the one of speciﬁc activ-
ity, i.e., whether the amount of the respective PAMP per bacterium
can account for the immunostimulating activity. Until recently, no
structure fulﬁlled this requirement. In contrast to the pg quantities
of LPS per ml required, ng per ml quantities of the Gram-positive
PAMP are needed. However, Deininger et al. (2008) were able to
show that presentation of LTA on a surface augments its stimula-
tory activity by 3–4 log orders. Similar ﬁndings are not available
for PGN and LP.
The Koch–Dale criteria are a very common framework to assess
the role of mediators for a given biological effect. Alternatively, it
is possible to structure an analysis of the role of the three surface
molecules in their interaction with the human innate immune
system with the criteria described by Bradford Hill for assessing
evidence of causation (Hill, 1965):
• Strength: The stronger an association between cause and effect
the more likely a causal interpretation, but a small association
does not mean that there is not a causal effect.
• Consistency: Consistent ﬁndings of different persons in differ-
ent places with different samples increase the causal role of a
factor and its effect.
• Speciﬁcity: The more speciﬁc an association is between factor
and effect, the bigger the probability of a causal relationship.
• Temporality: The effect has to occur after the cause.
• Biological gradient: Greater exposure should lead to greater
incidence of the effect with the exception that it can also be
inverse, meaning greater exposure leads to lower incidence of
the effect.
• Plausibility: A possible mechanism between factor and effect
increases the causal relationship,with the limitation that knowl-
edge of the mechanism is limited by best available current
knowledge.
• Coherence: A coherence between epidemiological and labo-
ratory ﬁndings leads to an increase in the likelihood of this
effect. However, the lack of laboratory evidence cannot nullify
the epidemiological effect on the associations.
• Experiment: Similar factors that lead to similar effects increase
the causal relationship of factor and effect.
Even though Bradford Hill did not intend to describe a checklist, it
is here used as a framework to group the data retrieved in the above
analysis for the three Gram-positive membrane components LTA,
PGN, and LP.
BRADFORD HILL CRITERIA
Strength
The strength of an association between factor and effect was
addressed by comparing cytokine induction of the stimulus versus
the non-stimulated cells. For LTA, cytokine induction occurred at
high induction levels compared to the control, as has been widely
described (Table 4), although pure PGN has been reported not to
be an immune stimulus (Travassos et al., 2004), and the commonly
used commercial peptidoglycan is considered to be contaminated
(Li et al., 2008). Even though the strength of evidence is low for
the puriﬁed component, a role in immune recognition cannot be
excluded, as PGN breakdown products such as muramyl dipeptide
(MDP) signal intracellularly via NOD (Girardin et al., 2003a,b).
For LP it is more difﬁcult to address this question, as there is cur-
rently no puriﬁed LP from Gram-positive bacteria available. The
synthetic derivates Pam3Cys-SK4 and Pam2Cys-SK4 are potent
inducers of cytokine release in cell lines (Buwitt-Beckmann et al.,
2005) but fail to induce higher cytokine amounts in complex
human systems like PBMCs or human whole blood (Draing et al.,
2008a).
Consistency
Lipoteichoic acids was prepared from many different species by
different groups at different places; the database for analysis of
cytokine induction by different LTAs is large (Tables 1 and 4).
Evidence for LTA is strong, as results are consistent over differ-
ent places and different experimenters. The ﬁndings for PGN not
contributing to cytokine release when highly puriﬁed (Travassos
et al., 2004) represent strong evidence for the absence of a causal
relationship in this case. For LP, however, ﬁndings may be consid-
ered as consistent for different persons and places, but the lack of
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LP preparations from a wide range of species leads to the lack of
different reports, as only synthetic derivates are broadly used. It is
still not clear whether these synthetic molecules really reﬂect the
natural situation.
Speciﬁcity
A high speciﬁcity of the effect would lead to a strong evidence
for a causal effect. The readout systems mentioned in this review
are based on reactions of the human innate immune system. This
system needs to react very quickly to threats and without speci-
ﬁcity as the intruder has to be reacted to. Hence, cytokine release
in complex human systems is an unspeciﬁc reaction. Here it is
only possible to draw conclusions based on the cytokine proﬁle of
the three cell wall components. LTA induces a broad spectrum of
cytokines, different from the spectra of PGN and LP. The widest
cytokine pattern is the one from whole bacteria, as they are able
to induce the whole range of human cytokines, as expected. It also
has been taken into account that synthetic LTA is able to induce
cytokines in humans in a similar manner to native LTA (Deininger
et al., 2003, 2007), which provides evidence for a speciﬁc reaction.
Synthetic lipoproteins are also able to induce cytokine induction
at least in cell lines (Buwitt-Beckmann et al., 2005). The speciﬁcity
of reactivity is shown only for LTA so far, using synthetic variants,
even deﬁned minimal structures (Deininger et al., 2003, 2007).
Temporality
As the effect has to occur after the stimulation to provide evidence
for a causal effect, it is here possible to fulﬁll this sub-point for LTA,
PGN, and LP as kinetics were reported in some cases for stimula-
tions. We can clearly say that cytokine release always occurs after
the stimulation with the three cell wall components.
Biological gradient
Increase of the stimulus concentration leads in all cases to an
increase in cytokine release, independent of whether the stimu-
lus is whole bacteria, LTA (Table 4), or PGN (Table 5). It was also
previously shown for synthetic lipoproteins (Buwitt-Beckmann
et al., 2005). Concentration-dependent cytokine induction has
been reported for all stimuli and therefore supports the evidence
of a causal relationship.
Plausibility
Next it is important to identify a plausible mechanism for the
interaction of LTA, PGN, and LP with the human innate immune
system, which would provide more evidence for a causal rela-
tionship between stimulus and cytokine release. Knowledge of a
receptor system of monocytes/macrophages to recognize the rele-
vant structures would represent such plausibility. Historically, LTA
was ﬁrst considered to signal via TLR4 (Takeuchi et al., 1999), but
this was found to be due to contaminations with LPS (Morath
et al., 2002a). Puriﬁed LTA was then considered to signal via TLR2
(Schwandner et al., 1999) with conﬁrmation by using a synthetic
LTA (Morath et al., 2002b). This was questioned again by using a
LTA from a SAΔlgt mutant lacking lipoproteins (Hashimoto et al.,
2006)with adecreased cytokine-inducing activity and loss of TLR2
dependence. Our own ﬁndings, however, show that this mutant
LTA is not able to induce cytokines in cell lines (Bunk et al., 2010)
but has normal cytokine-inducing activity in human whole blood
(von Aulock et al., 2007). This underlines the importance of Brad-
ford Hill’s statement that the knowledge of a mechanism is limited
by current knowledge (Hill, 1965). Note that there is a similar con-
troversy for PGN, which was ﬁrst described to be a TLR2 stimulus
(Takeuchi et al., 1999) but later was found not to be immunostim-
ulatory when highly puriﬁed (Travassos et al., 2004; Rockel et al.,
2011). At least for synthetic lipoproteins the mechanism appears
to be signaling via TLR2 (Parker et al., 2004). In addition, it is
important to mention that the three surface molecules are wide-
spread and highly conserved in Gram-positive bacteria. The fact
that synthetic molecules of LTA and LP display a somehow sim-
ilar cytokine-inducing activity leads to a prediction of a possible
speciﬁc mechanism for immune recognition even though these
mechanisms are still not fully understood and are somewhat con-
troversial.We canhere conclude that themechanism,and therefore
the speciﬁcity, is highly dependent on current general knowledge
of puriﬁcation procedures, experimental settings, and ligand–
receptor interactions. At least for LTA and lipoproteins, the causal
relationship is plausible for being recognized by TLR2, as well as
for PGN being recognized intracellularly by NOD molecules.
Coherence
A coherence between epidemiological and laboratory ﬁnding
would increase the causal connection between the stimuli and the
effect on cytokine release. Gram-positive bacteria are known to
have the potential to induce severe infections and sepsis in humans,
i.e., diseases associated with cytokine storms. So it is necessary to
address here the comparison between the spectrum of cytokine
release of whole bacteria and the puriﬁed components LTA, PGN,
and LP. Whole bacteria induce a wide range of cytokines (Hessle
et al., 2005). LTA was similar to this cytokine pattern (Rockel et al.,
2011). PGNand LP do not induce a similar number of cytokines in
the same human whole blood model (Rockel et al., 2011), which
suggests coherence mainly in the case of LTA. Additionally, LTA
was found to be detectable in patients with Streptococcus pneu-
moniae induced meningitis (Stuertz et al., 1998), which leads to
a higher probability of evidence for a causal relationship between
stimulus and effect. A high coherence between epidemiological
and laboratory ﬁnding thus only exists for LTA.
Another aspect of coherence is the similarity to the Gram-
negative counterpart: The factor most similar to the three surface
molecules LTA, PGN, and LP is the Gram-negative molecule LPS.
It is often used as a positive control stimulation and possesses a
structural similarity as amphiphilic molecule with lipid anchor to
LTA and lipoproteins (Schroder et al., 2008). No such similarity
exists with PGN.
Experiment
In experimental systems all structures have been shown to induce
cytokine release (see K/D criterion 2). The potency of LTA in
cytokine release compared to LPS is about 100- to 1000-fold lower
(Kimbrell et al., 2008), but LTA potency is still 100- to 10,000-fold
higher than for PGN (Travassos et al., 2004) or LP (Kimbrell et al.,
2008). The difference in potency to LPS is abolished when LTA is
presented on a surface (Deininger et al., 2008), a phenomenon not
observed for other stimuli.
In summary, LTA provides most evidence for a causal rela-
tionship of stimulus and effect based on Bradford Hill’s criteria,
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as all criteria are fulﬁlled to some extent. For PGN, four out of
eight criteria are fulﬁlled; the exceptions are strength, speciﬁcity,
coherence, and experiment. For strength it has to be noted that
the weak association here does not mean that there is no causal
connection between stimulus and effect, considering that PGN
breakdown products are recognized by the immune system. For
bacterial lipoproteins only four criteria are fulﬁlled, namely tem-
porality, biological gradient, plausibility, and experiment, with
a weaker evidence for a plausible mechanism as only synthetic
lipoproteins are available with a clearly investigated speciﬁc mech-
anismvia humanTLR2.The experimental response isweakdespite
structural similarity to LPS, results are consistent but do not come
from different studies, and the coherence with regard to the spec-
trum of cytokines induced is limited. In line with the Koch–Dale
criteria, the considerations suggested by Bradford Hill suggest
that LTA has a causal role in cytokine release by human mono-
cytes/macrophages inducible by Gram-positive bacteria (Table 8).
Finally, it is concluded that bacterial lipoproteins and PGN might
play a role in cytokine induction in humans, as no contradictory
results were found for human monocytes/macrophages. LTA is
the only Gram-positive membrane compound that fulﬁlls all of
the four Koch/Dale and all eight of the Bradford Hill Criteria.
This evaluation suggests that LTA is the appropriate reference
material for pyrogen testing. However, the fact that potency of
Table 8 | Fulfillment of Bradford Hill criteria for LTA, PGN, and LP
(personal weighing of evidence by the authors as explained in the
text).
LTA PGN LP
Strength +++ − −
Consistency +++ +++ −
Speciﬁcity ++ − +
Temporality +++ +++ +++
Biological Gradient +++ +++ +++
Plausibility +++ + ++
Coherence +++ − −
Experiment +++ − ++
LTA as monocyte activator is only fully exerted, i.e., ampliﬁed by
about 4 log orders (Deininger et al., 2008) when presented on a
surface, requires either the use of very high concentrations of pure
LTA or reliance on crude membrane preparations that present LTA
appropriately. Future developments might include the coating of
(nano-)particles with LTA to establish a pure highly active Gram-
positive reference material. For current validation efforts, the use
of bacterial lysates appears to be advisable, which also safeguards
the presence of possible pyrogenic response modiﬁers other than
LTA.
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